We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland

By LabMedica International staff writers
Posted on 23 Jan 2023
Print article
Image: The laboratory equipment R&D center launched in Swords, Ireland will explore breakthrough healthcare innovations (Photo courtesy of Siemens)
Image: The laboratory equipment R&D center launched in Swords, Ireland will explore breakthrough healthcare innovations (Photo courtesy of Siemens)

Siemens Healthineers (Erlangen, Germany) has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders. Siemens has been active in Swords since 1966, supplying medical diagnostic equipment to hospitals and laboratories. The site currently manufactures hematology and immunoassay analyzers and supports the continuous innovation of current and new products and the development of laboratory automation software, exported to more than 50 countries across all continents. Siemens will be making a multi-million-euro investment in the site, enabling clinicians to optimize patient care by bringing new levels of precision, efficiency and reliability to the diagnostic laboratories that serve them.

The investment by Siemens will span multiple years and more than double the existing engineering team, transforming the site into an innovation hub, growing knowledge, providing new training opportunities and developing a pool of expertise in immunoassay technology. The center will push the boundaries of science and engineering. Improvements to existing diagnostic techniques will enhance disease detection capabilities with the goal of delivering faster, higher precision results with improved patient insights. This will help to meet the extremely high throughput and complex needs of hospitals and laboratories in Ireland as well as globally. The project is supported by the Irish government through IDA Ireland.

“The investment at Swords will build on our existing expertise in healthcare manufacturing, adding a critical research and development focus," states Dr Dennis Gilbert, Head of R&D for Siemens Healthineers Diagnostics. "Partnering with IDA has enabled us to move forward in ways that would not have otherwise been feasible and will allow us to pioneer breakthroughs in healthcare, helping hospitals and laboratories across the globe to diagnose disease more effectively and efficiently.

Related Links:
Siemens Healthineers 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.